Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenylpropanolamine is a sympathomimetic small molecule that was widely used as a decongestant and appetite suppressant. It acts primarily as an indirect agonist of adrenergic receptors by promoting the release of norepinephrine, leading to vasoconstriction and reduced nasal congestion. It also inhibits norepinephrine reuptake at synaptic junctions. Phenylpropanolamine was commonly found in over-the-counter cold, allergy, and weight loss products but has been withdrawn from the market in many countries due to its association with an increased risk of hemorrhagic stroke, particularly in women. The drug is structurally related to amphetamine, ephedrine, and pseudoephedrine[1][3][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenylpropanolamine.